Panacea Biotec launches EasyFourPol in India
FDA Issues Form 483 to Panacea Biotec Pharma Ltd.
Shares of Panacea Biotech slumped around 5 percent intraday on October 13 after the US Food and Drug Administration slapped a Form 483 with nine observations on its biologics manufacturing plant in Baddi.
New Delhi: Two companies are conducting trials to develop a dengue vaccine, Dire .. nnRead more at: nhttps://health.economictimes.indiatimes.com/news/pharma/research-development/two-companies-are-conducting-trials-to-develop-a-dengue-vaccine-says-dg-icmr/100280244
Panacea Biotec Limited has reported total income of Rs. 129.14 crores during the period ended December 31, 2022 as compared to Rs. 115.57 crores during the period ended September 30, 2022.
Vaccine maker Panacea Biotec on Monday said it has received long-term supply contract worth $127.30 million (around INR 1,040 Crore) from UNICEF and Pan American Health Organization (PAHO) for supply of its WHO pre-qualified fully liquid Pentavalent vaccine, Easyfive-TT (DTwP-HepB-Hib).
Panacea Biotec Ltd. on Thursday said the U.S. health regulator has asked for further corrective actions at the manufacturing unit of its wholly-owned arm at Baddi in Himachal Pradesh otherwise approval of any pending product applications from the facility may be withheld.
Panacea Biotec yesterday said the US health regulator has asked for further corrective actions at the manufacturing unit of its wholly-owned arm at Baddi in Himachal Pradesh otherwise approval of any pending product applications from the facility may be withheld.
Panacea Biotec announced that the asset purchase agreement has been executed on 28 February 2022 for the sale of pharmaceutical formulation brands of the company's material subsidiary, Panacea Biotech Pharma in India and Nepal to Mankind Pharma for an aggregate consideration of Rs 1827 crore.